We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00678028
First Posted: May 15, 2008
Last Update Posted: April 23, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
HaEmek Medical Center, Israel
  Purpose
Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.

Condition
Recurrent Urinary Tract Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Biospecimen Retention:   Samples With DNA
whole blood for genetic test and serum for MBL test

Estimated Enrollment: 200
Study Start Date: February 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
young women with recurrent UTI - study group and young women witout recurrent UTI - a control group
Criteria

Inclusion Criteria:

  • women above 18 years old.
  • premenopausal
  • recurrent UTI

Exclusion Criteria:

  • pregnancy
  • immunocompromised
  • active malignancy
  • HIV carrier
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00678028


Locations
Israel
Ha'Emek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

Responsible Party: Dr. Orna Nitzan, Ha'emek Medical Center, Afula, Israel
ClinicalTrials.gov Identifier: NCT00678028     History of Changes
Other Study ID Numbers: 0080-07-EMC
First Submitted: February 17, 2008
First Posted: May 15, 2008
Last Update Posted: April 23, 2009
Last Verified: April 2009

Keywords provided by HaEmek Medical Center, Israel:
MBL, UTI

Additional relevant MeSH terms:
Infection
Communicable Diseases
Urinary Tract Infections
Urologic Diseases